We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALRS:RUSALROSA Analysis

Data as of 2026-03-12 - not real-time

$23.18

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Alerus Financial is trading above its short‑term moving average while remaining under its long‑term moving average, creating a mixed picture of momentum. The overall trend is flagged as bullish, yet the MACD histogram sits in negative territory, suggesting recent price weakness. RSI sits in the lower‑mid range, hinting at modest oversold pressure that could support a bounce. Current price is hugging a key support level with resistance positioned a few ticks higher, framing a narrow trading range. Volatility is elevated for the past month, but beta remains below the market, indicating lower systematic risk. Volume has been stable, providing adequate liquidity for short‑term moves.
Fundamentally, the price‑to‑earnings multiple is substantially above the sector average, pointing to an overvalued market price. The dividend yield is appealing, yet the payout ratio exceeds one hundred percent, raising questions about sustainability. A discounted cash‑flow model places fair value well below the market, limiting upside potential. The upside/downside projection shows modest upside, while the fear‑and‑greed gauge sits in greed territory, reflecting bullish sentiment despite the valuation concerns.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Negative MACD momentum
  • Price testing near support
  • Dividend yield offset by high payout ratio

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Attractive dividend yield
  • Stable sector fundamentals
  • Overvaluation relative to DCF

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • DCF fair value far below market price
  • Unsustainable dividend payout
  • Limited growth prospects in a high‑PE environment

Key Metrics & Analysis

Financial Health

Revenue Growth-85.80%
Profit Margin7.79%
P/E Ratio34.1
ROE3.29%
ROA0.33%
P/B Ratio1.0
Op. Cash Flow$67.5M
Industry P/E16.4

Technical Analysis

TrendBullish
RSI38.3
Support$23.01
Resistance$25.90
MA 20$24.50
MA 50$24.30
MA 200$22.48
MACDBearish
VolumeStable
Fear & Greed Index74.3

Valuation

Fair Value$11.50
Target Price$26.60
Upside/Downside14.75%
GradeOvervalued
TypeValue
Dividend Yield3.55%

Risk Assessment

Beta0.78
Volatility29.09%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.